The multitude of Python tools makes for many choices and many potential pitfalls. Streamline your AI projects by ...

To train artificial intelligence (AI) models, researchers need good data and lots of it. However, most real-world data has already been used, leading scientists to generate synthetic data. While the ...

Proponents of synthetic data see it as the future, saying it will help government have more access to valuable data while at the same time protecting individual privacy.

The Age of AI will rely on massive volumes of data that can be easily stored and retrieved—and bioscience may have an ingenious solution. A scientist examines a DNA (deoxyribonucleic acid) profile on ...

In an era defined by distrust in traditional institutions, the economic scoreboard Americans rely on—government-issued statistics like the Consumer Price Index (CPI) and Producer Price Index (PPI)—is ...

Google DeepMind researchers have a new way to take toxic data and clean it for AI training. It could prove to be a powerful ...

Nicole M. Bennett is affiliated with the Center for Refugee Studies at Indiana University. When the U.S. government signs contracts with private technology companies, the fine print rarely reaches the ...

Using less electricity as a response to high demand had been a nonstarter for big tech companies. That might be changing. For years, calculating the power needs for data centers has revolved around ...

Margaret Levenstein receives or has received funding from the National Science Foundation, the National Institutes of Health, and the U.S. Census Bureau. John Kubale receives funding from the National ...

An AT&T logo is seen on Aug. 17, 2025. An AT&T logo is seen on Aug. 17, 2025.Jonathan Raa—Getty Images. Reporter AT&T customers in the United States could be entitled to up to $7,500 after the ...

For the Tulalip Tribes in Washington state, the wetlands nestled in the tribe’s forests and coasts are far from humble swamps and simple ponds. They’re vital for climate resilience and biodiversity — ...

Imagine you are developing antibodies—drugs precisely aimed at a target, for example a viral protein or onco-marker. You test a series of antibodies and find that some work, while others do not.